Taurine in Peripartum Cardiomyopathy

NCT ID: NCT03907267

Last Updated: 2020-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-01

Study Completion Date

2020-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripartum Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Taurine

Group Type EXPERIMENTAL

Taurine Solution

Intervention Type DRUG

Taurine Solution

Saline

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type DIETARY_SUPPLEMENT

Normal Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Taurine Solution

Taurine Solution

Intervention Type DRUG

Normal Saline

Normal Saline

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Peripartum Cardiomyopathy

Exclusion Criteria

* Other identifiable cause for heart failure
* low LVEF ≤ 25%
* sepsis
* autoimmune disease
* severe chronic disease
* malignancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed S Sweed, MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University Maternity Hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AS1755

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cardiac Output in Preeclamptic
NCT05435573 UNKNOWN NA
Warfarine in Unexplained Oligohydramnios
NCT01569035 TERMINATED PHASE4
Fetal Cardiac Function
NCT06381258 COMPLETED
Diastolic Dysfunction 2025
NCT07190846 COMPLETED
Hypertonic Saline Use in Preeclampsia
NCT00181077 COMPLETED PHASE1